Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Authors
Keywords
CML, BCR-ABL1, TKI, Imatinib, Dasatinib, Nilotinib
Journal
Current Hematologic Malignancy Reports
Volume 11, Issue 2, Pages 71-79
Publisher
Springer Nature
Online
2016-02-27
DOI
10.1007/s11899-016-0309-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
- (2015) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
- (2015) S. Saussele et al. BLOOD
- Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
- (2015) Niklas Gunnarsson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2015) Musa Yilmaz et al. CANCER
- Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
- (2015) G. Gugliotta et al. HAEMATOLOGICA
- Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
- (2015) Javid J. Moslehi et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic myeloid leukaemia
- (2015) Jane F Apperley LANCET
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
- (2015) F Castagnetti et al. LEUKEMIA
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
- (2015) G. Gugliotta et al. HAEMATOLOGICA
- Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study
- (2015) Sabin Nsanzimana et al. Lancet HIV
- OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
- (2015) Grzegorz Helbig et al. Mediterranean Journal of Hematology and Infectious Diseases
- Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment
- (2014) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Optimizing tolerability of TKI therapy in CML
- (2014) A. Hochhaus BLOOD
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
- (2014) T. P. Hughes et al. BLOOD
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
- (2014) P. Valent et al. BLOOD
- Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
- (2014) Tim H. Brümmendorf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies
- (2014) José O Alemán et al. ENDOCRINE-RELATED CANCER
- Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
- (2014) Frédéric Millot et al. EUROPEAN JOURNAL OF CANCER
- Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy
- (2014) Giuseppe Bronte et al. Expert Opinion On Drug Safety
- Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia
- (2014) D. Rea et al. HAEMATOLOGICA
- The Capable ABL: What Is Its Biological Function?
- (2014) J. Y. J. Wang MOLECULAR AND CELLULAR BIOLOGY
- Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
- (2014) Joost C. M. Uitdehaag et al. PLoS One
- Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
- (2013) H. M. Kantarjian et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study
- (2013) Sarah Farmer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study
- (2013) Luciano Levato et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Nilotinib-induced interstitial lung disease
- (2013) Se-Il Go et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
- (2013) A Tefferi LEUKEMIA
- Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
- (2013) T D Kim et al. LEUKEMIA
- Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
- (2013) F J Giles et al. LEUKEMIA
- The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia
- (2013) Emi Togasaki-Yoshimoto et al. LEUKEMIA & LYMPHOMA
- Cancer-Drug Discovery and Cardiovascular Surveillance
- (2013) John D. Groarke et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis
- (2013) Karthik R. Narayanan et al. PEDIATRIC BLOOD & CANCER
- Nilotinib-Associated Vascular Events
- (2012) Alfonso Quintás-Cardama et al. Clinical Lymphoma Myeloma & Leukemia
- Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
- (2012) F. Giona et al. HAEMATOLOGICA
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Secondary malignancy after imatinib therapy: eight cases and review of the literature
- (2012) Berna Bozkurt Duman et al. LEUKEMIA & LYMPHOMA
- Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index
- (2012) Massimo Breccia et al. LEUKEMIA RESEARCH
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
- (2011) Karl J. Aichberger et al. AMERICAN JOURNAL OF HEMATOLOGY
- Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients
- (2011) M. S. Marcolino et al. ANNALS OF ONCOLOGY
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
- (2011) D. Verma et al. BLOOD
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
- (2011) F. Efficace et al. BLOOD
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- Severe Peripheral Arterial Disease During Nilotinib Therapy
- (2011) P. Le Coutre et al. JNCI-Journal of the National Cancer Institute
- What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
- (2011) Michael W. Deininger et al. LEUKEMIA RESEARCH
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
- (2010) Hui Cheng et al. CIRCULATION RESEARCH
- Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia
- (2010) Rishard Salie et al. Clinical Lymphoma Myeloma & Leukemia
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiotoxicity induced by tyrosine kinase inhibitors
- (2009) George S. Orphanos et al. ACTA ONCOLOGICA
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started